DWTX

#3995
Dogwood Therapeutics, Inc. - Common Stock
2.5 8 USD
-0.03%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
2.58
2.58
Intervallo Annuale
1.28
3.50
Variazione giornaliera
-2.64%
Variazione Mensile
+56.36%
Variazione di 6 mesi
-9.95%
Variazione Annuale
-14.00%
Chiusura Precedente
2.6 5
Open
2.5 8
Minimo
2.5 8
Massimo
2.5 8
Volume
4
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Dogwood Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Dogwood Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Dogwood Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Dogwood Therapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Dogwood Therapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Dogwood Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Dogwood Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Dogwood Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Dogwood Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Dogwood Therapeutics, Inc. current report, Q1 FY2026
8-K

Dogwood Therapeutics, Inc. current report, Q2 FY2026

Full document

Business Context and Reporting Period

This Form 8-K Current Report from Dogwood Therapeutics, Inc. (DWTX) covers events occurring on June 16, 2026, specifically the Company's Annual Meeting of Stockholders. The filing details the outcomes of shareholder votes and the subsequent amendment to the Company's Certificate of Incorporation.

Key Financial Metrics

This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. No financial statements are included in this document.

Material Changes and Corporate Actions

  • Amendment to Certificate of Incorporation: Shareholders approved an amendment to increase the number of authorized common and preferred shares. The amendment was filed with the Delaware Secretary of State on June 17, 2026, and became effective immediately.
  • Director Elections: All seven nominees were elected to the Board of Directors with overwhelming support (approximately 97.5% "For" votes).
  • Accounting Firm Ratification: Shareholders ratified the appointment of Forvis Mazars, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
  • Shareholder Participation: Holders of 31,791,500 shares (95.17% of voting power) were present, constituting a quorum.

Guidance, Outlook, and Governance Decisions

  • Say-on-Frequency: Shareholders voted to hold advisory votes on executive compensation frequency annually ("One Year"). Consequently, the Board determined that future proxy materials will include an annual vote on executive compensation.
  • Say-on-Pay: The advisory vote on named executive officer compensation was approved with approximately 99.1% "For" votes.
  • Risks and Contingencies: The filing does not disclose new material risks, contingencies, or unusual items beyond standard corporate governance procedures.

Investor Verification Checklist

  • Verify the specific increase in authorized share capital by reviewing Exhibit 3.1 (Certificate of Amendment) attached to the filing.
  • Confirm the effective date of the Certificate of Amendment (June 17, 2026) with the Delaware Secretary of State records.
  • Review the definitive proxy statement filed on April 27, 2026, for detailed rationale behind the share authorization increase.
  • Monitor future filings for the first annual Say-on-Pay vote as mandated by the June 16, 2026, shareholder decision.